Physician profile
Amanda K Light
NPI 1710530571
$8,185.65
in general payments reported to CMS, 2019-2025
28 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $1,873 · 2023: $1,531 · 2024: $1,803 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,877 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,876.66 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,486.31 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $1,463.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $683.20 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.31 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $563.10 | 2021-2025 | |
| Dexcom, INC. | $479.56 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $402.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $252.95 | 2023-2025 | |
| Insulet Corporation | $245.66 | 2023-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $245.40 | 2021-2022 | |
| Radius Health, INC. | $224.59 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $198.17 | 2021-2025 | Korlym |
| Abbvie INC. | $191.32 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $190.52 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $173.10 | 2021-2025 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $128.22 | 2022-2025 | Repatha, Evenity, Prolia |
| Medtronic, INC. | $116.04 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $103.88 | 2021 | |
| Neurocrine Biosciences, INC. | $78.33 | 2024-2025 | |
| Lifescan, INC. | $49.82 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $47.93 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $47.51 | 2022-2023 | Unithroid |
| Ibsa Pharma INC. | $42.21 | 2022-2025 | Tirosint, Flector, Licart |
| Sequel Med Tech, LLC | $40.35 | 2025 | Twiist |
| Cequr Corporation | $34.42 | 2024-2025 | Cequr Simplicity |
| Antares Pharma, INC. | $32.18 | 2022-2024 | Xyosted |
| Averitas Pharma INC. | $25.41 | 2025 | Qutenza |
| Intra-Sana Laboratories | $13.90 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.